Non-Small Cell Lung Cancer with Comorbid Interstitial Pneumonia
Conditions
Interventions
None listed
Sponsors
The Diffuse Lung Diseases Research Group from the Ministry of Health, Labour, and Welfare in Japan
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Pathologically diagnosed Non-Small Cell Lung Cancer (NSCLC) by cytological or histological diagnosis. 2. Unresectable stage III/IV/postoperative recurrence 3. If stage III/IV, the examination that led to the diagnosis of NSCLC was conducted between June 1, 2019 and June 30, 2024. If postoperative recurrence, the diagnosis of postoperative recurrence was made between June 1, 2019 and June 30, 2024 4. The attending physician or the responsible physician/sub-investigator at each institutions has diagnosed the patient as having chronic fibrosing interstitial pneumonia in the background lung 5. Idiopathic interstitial pneumonia or any of the following secondary interstitial pneumonias ([1] fibrosing hypersensitivity pneumonitis, [2] occupational lung disease/pneumoconiosis, [3] collagen vascular disease/vasculitis)
Exclusion criteria
Exclusion criteria: 1. Iatrogenic secondary interstitial pneumonia (1. radiation pneumonitis, 2. drug-induced pneumonitis, 3. other) 2. Interstitial Lung Abnormality identified retrospectively
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Implementation rate of Testing for Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer with Comorbid Interstitial Pneumonia | — |
Countries
Japan
Contacts
Public ContactSatoshi Ikeda
Kanagawa Cardiovascular and Respiratory Center Department of Respiratory Medicine
Outcome results
None listed